Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Stephen Gracon, D.V.M., Joins the NanoBio Team as Vice President of Regulatory Affairs

Abstract:
NanoBio(R) Corporation, a biopharmaceutical company focused on developing and commercializing novel products for the prevention and treatment of infectious diseases, today announced the addition of Stephen Gracon, D.V.M., as Vice President of Regulatory Affairs.

Stephen Gracon, D.V.M., Joins the NanoBio Team as Vice President of Regulatory Affairs

ANN ARBOR, MI | Posted on January 16th, 2008

In his new role, Dr. Gracon will lead the regulatory and quality assurance activities for the company's rich pipeline of anti-infective products and mucosal vaccines.

Dr. Gracon brings 30 years of experience to NanoBio in diverse areas within the pharmaceutical industry, including pathology and experimental toxicology, clinical research, and regulatory affairs within the United States and internationally. Dr. Gracon served in various clinical, research and regulatory positions at Parke-Davis, Pfizer, Amgen and Baxter prior to joining NanoBio. He has a unique combination of experience with both small and large molecules in a broad range of indications, as well as with seasonal and pandemic vaccines and plasma-derived products.

"NanoBio's platform is very unique and has tremendous potential far beyond the current indications under investigation," said Dr. Gracon. "My role is to develop and execute strategies with the NanoBio team to navigate and expedite the FDA approval process for the numerous topical agents and vaccines that can be developed from our proprietary nanotechnology platform."

"We are very fortunate to have Dr. Gracon's extensive regulatory experience as we prepare for multiple regulatory submissions," added James Baker Jr., M.D., founder and CSO of NanoBio Corporation. "His specialized knowledge of regulatory protocol for both therapeutics and vaccines will be critical to moving NanoBio's products to FDA approval."

####

About NanoBio Corporation
NanoBio(R) Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.

For more information, please click here

Contacts:
NanoBio® Corporation

2311 Green Road, Suite A
Ann Arbor, Michigan 48105
Telephone:734.302.4000
Fax:734.302.9150
V.P. Business Development:
John Coffey (Ext. 107)

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

The mysterious 'action at a distance' between liquid containers November 26th, 2014

'Giant' charge density disturbances discovered in nanomaterials: Juelich researchers amplify Friedel oscillations in thin metallic films November 26th, 2014

Vegetable oil ingredient key to destroying gastric disease bacteria: In mice, therapeutic nanoparticles dampen H. pylori bacteria and inflammation that lead to ulcers and gastric cancer November 25th, 2014

Research yields material made of single-atom layers that snap together like Legos November 25th, 2014

Nanomedicine

Vegetable oil ingredient key to destroying gastric disease bacteria: In mice, therapeutic nanoparticles dampen H. pylori bacteria and inflammation that lead to ulcers and gastric cancer November 25th, 2014

Research reveals how our bodies keep unwelcome visitors out of cell nuclei November 24th, 2014

ASU, IBM move ultrafast, low-cost DNA sequencing technology a step closer to reality November 24th, 2014

An Inside Job: UC-Designed Nanoparticles Infiltrate, Kill Cancer Cells From Within November 24th, 2014

Announcements

The mysterious 'action at a distance' between liquid containers November 26th, 2014

'Giant' charge density disturbances discovered in nanomaterials: Juelich researchers amplify Friedel oscillations in thin metallic films November 26th, 2014

Vegetable oil ingredient key to destroying gastric disease bacteria: In mice, therapeutic nanoparticles dampen H. pylori bacteria and inflammation that lead to ulcers and gastric cancer November 25th, 2014

Research yields material made of single-atom layers that snap together like Legos November 25th, 2014

Appointments/Promotions/New hires/Resignations/Deaths

Mining entrepreneur Julian Malnic Joins Deep Space Industries’ Board: Deep Space Industries welcomes a prolific mining entrepreneur and accomplished company builder, Julian Malnic, to its Board of Directors November 14th, 2014

SEMATECH Names Ronald Goldblatt Permanent Chief Executive Officer November 7th, 2014

First Canada Excellence Research Chair gets $10 million from the federal government for oilsands research at the University of Calgary: Federal government announces prestigious research chair to study improving oil production efficiency October 19th, 2014

VDMA photonics steering committee with new members stronger than ever October 14th, 2014

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More












ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE